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Abstract
Objective: Neonatologists still commonly use creatinine as a proxy for renal clearance, despite
issues related to neonatal (patho)physiology and methodology (assay variability). Cystatin C
(CysC) has been suggested to be a more reliable biomarker, but assay related differences have
also been reported in children and adults. We are unaware of any review on the assay related
impact on CysC reference values in newborns.
Methods: A structured literature search was performed on published CysC values in (pre)term
neonates.
Results: The extensive range (45-fold) in serum CysC observations in neonates in part relates to
the fact that CysC concentrations are higher at birth with subsequent decrease and that CysC
concentrations are higher in preterm compared to term neonates. The CysC assay matters while
disease characteristics also affect CysC values, but not always in the predicted direction.
Conclusions: Similar to creatinine, the extensive CysC range in neonates is only in part explained
by renal (patho)physiology. Its applicability in neonatal medicine can be further improved by
use of assay specific reference values, adapted to neonatal renal physiology (e.g. weight, age)
and should be compared to a gold standard such as inulin clearance.
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Introduction
Glomerular filtration rate (GFR) in early life is very low and
can only be maintained due to a delicate balance between
both vasodilatory effects at the afferent arterioli (e.g. pros-
taglandins) as well as vasoconstrictive effects at the efferent
glomerular arterioli (e.g. angiotensin II). Despite this low
clearance capacity, the GFR variability within this population
is extensive (at least 5-fold) and can in part be predicted by
covariates like e.g. gestational age, birth weight, postnatal
age, drugs, growth restriction or peripartal asphyxia, but also
assay (Jaffe or enzymatic) related differences [1–7]. Despite
this variability, GFR is a relevant parameter, since renal
dysfunction is associated with increased mortality and
morbidity (e.g. retinopathy of prematurity, neurodevelop-
mental impairment) in neonates, and is crucial to tailor
pharmacotherapy or fluid exposure to the individual newborn
[1–7]. Furthermore, an association of extreme preterm birth
and renal dysfunction in later life has been described [1,7].
At present, serum creatinine is commonly measured as a
proxy for renal (dys)function. However, before creatinine
values can be used to estimate renal elimination capacity,
there are some specific aspects related to (patho)physiology
and bio-analysis that need to be considered. Creatinine at
birth does not yet reflect neonatal but maternal creatinine
[1,8]. Moreover, because of passive tubular back leak instead
of active secretion, creatinine clearance does not yet fully
reflects GFR. Finally, creatinine values also depend on the
technique (Jaffe or enzymatic assays) used for its measure-
ment [1,6,7]. The move towards harmonization through
isotope dilution mass spectrometry (IDMS) traceability
helped to reduce the extent of the between assay differences,
but has not fully abolished the problem [1,9,10].
Low molecular weight proteins (e.g. Cystatin C, beta-trace
protein, beta-2 microglobulin, alfa-1 microglobulin) have
been suggested to be more reliable biomarkers [11–13] to
estimate renal elimination capacity and – related to this – risk
assessment based on kidney function in adult patients [14]. It
is hereby has been assumed that Cystatin C (CysC) is not
affected by gender, body muscle mass, age, inflammation or
nutritional conditions [14,15] although these assumptions and
claims are not yet sufficiently supported by data in early
infancy [7].
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CysC is a low-molecular mass (13 kDa) basic protein and
belongs to the cystatin superfamily of reversible inhibitors of
cysteine proteases. It is a proteinase inhibitor involved in
normal intracellular protein turnover. Consequently, CysC is
produced at a constant rate by any nucleated cell, and is
eliminated exclusively through glomerular filtration. After
ultrafiltration through the glomerular basal membrane, CysC
is metabolized in the proximal renal tubular cell following
endocytosis at the apical brush border of the renal tubular cell
[7,9,13]. Consequently, serum CysC reflects GFR, while
urinary CysC reflects renal tubular dysfunction.
Unfortunately, before CysC can be considered to be a good
biomarker for renal elimination capacity in newborns, similar
aspects as related to creatinine should be considered. An
important advantage is that – as compared to creatinine –
CysC does not cross the placental barrier [16]. Consequently
and in contrast to creatinine, there is no correlation between
maternal and umbilical cord blood CysC observations [8,16].
However, the daily caloric needs and metabolic activity are
significantly different in early infancy while renal tubular cell
transport activity also displays extensive maturation. This
may affect CysC production or CysC elimination respectively.
Finally and comparable to creatinine, there are different
methods reported to quantify CysC with suboptimal diagnos-
tic performance because of imprecision, between assay
differences, over-recovery or between laboratory differences
[17,18]. Until now, this assay related issue remained unex-
plored in this specific population.
At present, there are at least three different registered
methods for serum CysC analysis. Besides particle-enhanced
nephelometric immune-assays (PENIA), the use of particle-
enhanced turbimetric immune-assays (PETIA) and enzyme-
linked immune-assays (ELISA) methods have been reported
and paired analysis confirmed between assay differences [17].
For both PENIA and PETIA, specific GFR equations have
been developed in adults and children [9,13,18]. This resulted
in the suggestion of Li et al. to apply assay-specific cystatin C
based GFR equations or estimators, until an international
calibration for CysC – similar to the above mentioned IDMS
approach for creatinine – has been developed [18]. Since we
are unaware of any review on assay-specific relevance of
CysC reference values in newborns, we performed an
extensive literature search to collect information on CysC
reference values and its covariates in neonates.
Methods
An electronic bibliographic search was performed, using
PubMed and EMBASE as search engines. Keywords were
‘‘infant’’, ‘‘newborn’’ or ‘‘preterm’’ and ‘‘Cystatin C’’ with a
cut-off point in time (August 2014). Retrieved sources were
further explored applying both the snowball approach
Table 1. Cystatin C (CysC) reference values as reported in literature in full term healthy neonates in the first 30 days of postnatal
life (PENIA¼ particle enhanced nephelometric immune-assay; PETIA¼ particle enhanced turbimetric immune-assay;
ELISA¼ enzyme linked immune-sorbent assay, SD¼ standard deviation) [16,19–30].
Paper Technique Clinical characteristics Cys C values (mg/L)
[19] PETIA, CysC PET kit, DAKO Day 1, n¼ 50 (cord blood) 2.23 (range 1.17–4.84)
Day 3, n¼ 50 1.82 (range 0.85–3.09)
Day 5, n¼ 50 1.63 (range 0.66–1.63)
[20] PETIA, CysC PET kit, DAKO 53days, n¼ 23 2.16 (range 1.64–2.59)
[20] PETIA, CysC PET kit, DAKO Day 3–30, n¼ 14 2.02 (range 1.52–2.40)
[16] PETIA, CysC PET kit, DAKO Day 1, n¼ 78 (cord blood) 2.11 (1.45–2.81)
Day 3, n¼ 78 1.75 (0.85–2.52)
Day 5, n¼ 78 1.63 (0.86–2.09)
[21] PETIA, in house Day 1–7, n¼ 50 1.70 (SD 0.26)
[22] PENIA Day 1, n¼ 112 1.36 (SD 0.35)
N Latex CysC, Dade Behring Day 3, n¼ 98 1.35 (SD 0.33)
[23] PENIA Day 1, 36 weeks, n¼ 24 1.84 (range 1.32–2.63)
N Latex CysC, Dade Behring Day 3, 36 weeks, n¼ 21 1.58 (range 1.16–1.95)
[24] PENIA Day 1, n¼ 21 (cord blood) 1.70 (SD 0.26)
N Latex CysC, Dade Behring Day 3, n¼ 21 1.51 (SD 0.19)
Day 7, n¼ 21 1.54 (SD 0.15)
Day 28, n¼ 21 1.51 (SD 0.15)
[25] PENIA, DAKO Cytomation Day 1, n¼ 100 (cord blood) 2.02 (range 1.40–2.70)
[26] ELISA Day 1, n¼ 22 2.23 (range 1.75–2.62)
Quantikine Human CysC Day 3, n¼ 22 2.14 (range 1.55–2.54)
Day 10, n¼ 22 2.48 (range 2.35–2.99)
[27] PENIA, CysC Dade Behring Day 1, n¼ 33 (cord blood) 1.21 (SD 0.30)
[28] Latex agglutinin immuno-assay Day 0–3, n¼ 119 1.64 (SD 0.32)
(not further defined) Day 4–6, n¼ 99 1.42 (SD 0.26)
Day 7–10, n¼ 97 1.51 (SD 0.23)
Day 11–15, n¼ 44 1.55 (SD 0.29)
Day 16–21, n¼ 27 1.55 (SD 0.34)
Day 22–30, n¼ 14 1.56 (SD 0.39)
[29] PENIA Day 3–7, n¼ 40 1.33 (SD 0.18)
N Latex CysC, Dade Behring
[30] PENIA Day 1, n¼ 50 (cord blood) 1.39 (SD 0.19)
N Latex CysC, Dade Behring Day 3, n¼ 50 1.34 (SD 0.21)
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(verifying the references) as well as verifying for citations of
these original papers through Isi-knowledge and PubMed.
Corresponding authors were contacted for additional infor-
mation on assay related issues if this was not sufficiently
clearly described in the original source document.
CysC reference values were extracted from these source
documents based on mean and standard deviation, median and
range or reference value as published by the authors and were
classified based on the clinical characteristics [healthy term
(Table 1), healthy preterm (Table 2), specific disease
characteristics (Table 3)] with explicit reference to the assay
used to quantify CysC.
Results
Based on the bibliographic search, data in 13 cohorts of
healthy term cases (1549 CysC measurements, day 1–30,
Table 1) [16,19–30] and in 12 cohorts of healthy preterm
cases (1 519 CysC measurements, day 1–30, gestational age
24–36 weeks, Table 2) [24,28,30,32–37] were retrieved.
Table 2. Cystatin C (CysC) reference values as reported in literature in preterm healthy neonates in the first 30 days of postnatal life.
Paper Technique Clinical characteristics Cys C values (mg/L)
[31] PENIA, CysC Dade Behring Day 8–30, n¼ 12 1.63 (SD 0.26)
[32] PETIA, in house Day 1, 24–28 weeks (n¼ 16) 1.48 (range 0.65–3.37)
Day 1, 29–36 weeks (n¼ 14) 1.65 (range 0.62–4.42)
[21] PETIA, in house Day 1–7, 32 (range 25–37) weeks (n¼ 58) 1.88 (SD 0.36)
[33] PETIA, CysC PET kit, DAKO Day 4–7, 33 (range 28–34) weeks (n¼ 20) 1.88 (range 1.20–2.30)
[34] PENIA, CysC Dade Behring Day 1, 32.5 (SD 2.6) weeks (n¼ 108, cord blood) 1.8 (SD 0.30)
Day 3, 32.5 (SD 2.6) weeks, (n¼ 108) 1.65 (SD 0.30)
[23] PENIA Day 1, 24–28 weeks (n¼ 22) 1.63 (range 1.17–2.24)
N Latex CysC Day 3, 24–28 weeks (n¼ 23) 1.47 (range 1.14–2.08)
Day 1, 28–32 weeks (n¼ 33) 1.79 (range 1.05–2.41)
Day 3, 28–32 weeks (n¼ 33) 1.60 (range 1.07–2.17)
Day 1, 32–36 weeks (n¼ 29) 1.89 (range 0.58–2.93)
Day 3, 32–36 weeks (n¼ 37) 1.64 (range 1.17–2.19)
[27] PENIA, N Latex CysC, Dade Behring Day 1, 33–36 weeks (n¼ 30, cord blood) 1.21 (SD 0.31)
Day 1, 28–32 weeks (n¼ 35, cord blood) 1.41 (SD 0.27)
[35] not defined Day 1, 24–26 weeks (n¼ 17) 1.80 (range 0.80–2.20)
Day 3, 24–26 weeks (n¼ 17) 1.52 (range 0.54–2.00)
Day 1, 26–28 weeks (n¼ 19) 1.80 (range 1.51–3.19)
Day 3, 26–28 weeks (n¼ 19) 1.61 (range 1.10–3.41)
Day 1, 28–30 weeks (n¼ 32) 1.80 (range 0.65–2.48)
Day 3, 28–30 weeks (n¼ 32) 1.70 (range 0.56–2.31)
Day 1, 30–32 weeks (n¼ 45) 1.79 (range 0.68–2.31)
Day 3, 30–32 weeks (n¼ 45) 1.61 (range 0.92–2.21)
[36] PENIA, N Latex CysC, Dade Behring Day 3, 27–29 weeks (n¼ 11) 1.34 (SD 0.10)
Day 30, 27–29 weeks (n¼ 11) 1.32 (SD 0.20)
Day 3, 30–32 weeks (n¼ 23) 1.28 (SD 0.20)
Day 30, 30–32 weeks (n¼ 23) 1.27 (range 0.68–1.58)
[37] PENIA, N Latex CysC, Dade Behring Day 3, 28–29 weeks (n¼ 11) 1.34 (SD 0.1)
Day 3, 30–32 weeks (n¼ 23) 1.28 (SD 0.2)
Day 3, 33–34 weeks (n¼ 18) 1.24 (SD 0.2)
Day 30, 28–29 weeks (n¼ 11) 1.32 (SD 0.2)
Day 30, 30–32 weeks (n¼ 23) 1.25 (SD 0.1)
Day 30, 33–34 weeks (n¼ 18) 1.22 (SD 0.2)
[28] Latex agglutinin immuno-assay Day 0–3, 28 weeks (n¼ 15) 1.60 (SD 0.21)
not further defined Day 0–3, 29–32 weeks (n¼ 40) 1.56 (SD 0.28)
Day 0–3, 33–36 weeks (n¼ 72) 1.67 (SD 0.25)
Day 4–6, 28 weeks (n¼ 12) 1.55 (SD 0.28)
Day 4–6, 29–32 weeks (n¼ 21) 1.53 (SD 0.21)
Day 4–6, 33–36 weeks (n¼ 46) 1.68 (SD 0.27)
Day 7–10, 28 weeks (n¼ 11) 1.73 (SD 0.41)
Day 7–10, 29–32 weeks (n¼ 30) 1.75 (SD 0.29)
Day 7–10, 33–36 weeks (n¼ 61) 1.69 (SD 0.32)
Day 11–15, 28 weeks (n¼ 14) 1.87 (SD 0.26)
Day 11–15, 29–32 weeks (n¼ 22) 1.87 (SD 0.31)
Day 11–15, 33–36 weeks (n¼ 25) 1.72 (SD 0.24)
Day 16–21, 28 weeks (n¼ 8) 1.80 (SD 0.28)
Day 16–21, 29–32 weeks (n¼ 26) 1.68 (SD 0.31)
Day 16–21, 33–36 weeks (n¼ 26) 1.81 (SD 0.22)
Day 22–30, 28 weeks (n¼ 11) 2.02 (SD 0.42)
Day 22–30, 29–32 weeks (n¼ 23) 1.84 (SD 0.27)
Day 22–30, 33–36 weeks (n¼ 20) 1.64 (SD 0.23)
[29] PENIA, N–latex CysC Dade–Behring Day 3–7, 34 (SD 3) weeks (n¼ 60) 1.42 (SD 0.21).
PENIA¼ particle enhanced nephelometric immune-assay; PETIA¼ particle enhanced turbimetric immune-assay; ELISA¼ enzyme linked immune-
sorbent assay, SD¼ standard deviation [24,28,30,32–37].
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In search for specific disease characteristics, we retrieved
information on the impact of gentamicin exposure, peripartal
asphyxia, umbilical cord pH, congenital renal anomalies,
renal dysfunction, respiratory distress with or without acute
kidney injury, and sepsis/severe sepsis/septic shock on CysC
measurements (Table 3) [25,29,30,33,36,38,39]. Cohorts were
reported chronologically. Pooled CysC measurements in
preterm and term cases, or in neonates and young infants
were not retained in these tables.
Discussion: how to aim for a moving target?
The quality of neonatal care depends on the availability of
reference intervals for any specific laboratory test or
biomarker to support prognosis, clinical decision making or
to tailor therapy [7,40,41]. Since maturational variability is
most prominent in early infancy, the crucial issue is how to
disentangle the signal from the noise, as illustrated in the
extensive variability in CysC reference values. This variabil-
ity in part is due to physiological changes (e.g. gestational or
postnatal age, weight) (Tables 1 and 2) as well as changes
related to pathophysiology (e.g. peripartal asphyxia, co-
medication, haemoglobin, respiratory distress) (Table 3).
Besides these (patho)physiogical covariates, we also found
arguments on the relevance of assay differences in newborns
to explain the range in CysC values reported.
In essence, (i) CysC concentrations are higher at birth,
with a subsequent decrease in term as well as preterm
neonates, (ii) CysC concentrations are higher in preterm
neonates when compared to term neonates, with the highest
values in the most immature cases, (iii) CysC assays also
matter for neonates. Even if we limit the analysis to blood
samples in healthy term neonates in the first 24 h of life to
restrict the impact of covariates, there is significant difference
in mean values reported following PETIA [16,19,20] or
ELISA [26] compared to PENIA assays [21,23,27,28,30], as
illustrated in Figure 1. Finally, (iv) disease characteristics like
respiratory distress [36], bilateral kidney abnormalities [25],
peripartal asphyxia [30,38], aminoglycoside exposure [29],
hemoglobin [30,38], renal dysfunction [33,37] or sepsis [39]
also affect the CysC values observed, but not always in the
expected direction. Aminoglycoside exposure in preterm
neonates resulted in slightly lower serum CysC values,
Table 3. Plasma cystatin C (CysC) values in neonates with specific perinatal disease characteristics.
Reference Assay Clinical characteristics CysC values
[33] PETIA Preterms (n¼ 20), Postnatal 4–7 days 1.88 (1.2–2.3) mg/L
28–34 weeks, birth weight 910–2250 g
Raised CysC in cases with lower inulin clearance
[38] PENIA n¼ 75, umbilical blood at birth (34–41 weeks) 1.97 (SD 0.60) mg/l
Raised CysC with pH57.2 at birth
Correlation (r¼ 0.28) with hemoglobin
[25] PENIA 100 controls (term), all umbilical cord blood 2.02 (1.54–2.64) mg/l
13 congenital renal anomaly cases, bilateral 2.52 (1.80–3.50) (+24.5%)mg/l
[39] ELISA 32 neonates, 34–40 weeks, 0 and 48 h
Sepsis 1.47 (1.01–1.9) to 1.43 (1.05–1.81) mg/l
Severe sepsis 1.5 (1.12–1.87) to 1.31 (1.05–1.58) mg/l
Septic shock 1.23 (0.92–1.54) to 1.21 (0.95–1.47) mg/l
[36] PENIA 34 cases without respiratory distress, day 3 1.30 (SD 0.2) mg/l
28 cases with respiratory distress, day 3
No acute kidney injury (22/28) 1.14 (SD 0.1) mg/l
Acute kidney injury (6/28) 1.49 (SD 0.09) mg/l
34 cases without respiratory distress, day 30 1.29 (0.68–1.67) mg/l
28 cases with respiratory distress, day 30
No acute kidney injury (22/28) 1.40 (1.01–1.89) mg/l
Acute kidney injury (6/28) 1.51 (1.16–1.70) mg/l
[29] PENIA Preterm, 34 (SD 3) weeks 1.35 (SD 0.19) to 1.47 (SD 0.21) mg/l
Second part of first week of life
26/60 exposed to gentamicin (CysC lower)
[30] PENIA 50 term cases perinatal asphyxia/controls
At birth (umbilical cord blood) 2.12 (SD 0.53) to 1.39 (SD 0.19) mg/l
On day 3 of life (venous blood) 1.56 (SD 0.32) to 1.34 (SD 0.21) mg/l
PENIA¼ particle-enhanced nephelometric immune-assay; PETIA¼ particle-enhanced turbimetric immune-assay; ELISA¼ enzyme linked immune-
sorbent assay, SD¼ standard deviation [25,29,30,33,36,38,39].
2,4
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Figure 1. Mean Cystatin C (CysC) values in 9 cohorts of healthy term
newborns (524 h) of life were retrieved in the literature. In 5 of these
cohorts, CysC measurement was based on PENIA [21,23,27,28,30],
there was one ELISA measurement [26] and 3 PETIA [16,19,20] based
measurements. Mean values following PENIA were significantly lower
when compared to non-PENIA techniques [PENIA¼ particle enhanced
nephelometric immune-assay; PETIA¼ particle enhanced turbimetric
immune-assay; ELISA¼ enzyme linked immune-sorbent assay].
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suggesting higher clearance [29]. Similar, neonates in septic
shock had lower CysC values when compared to neonates
with (severe) sepsis [39]. This strongly suggests that besides
aspects related to the CysC assay, additional clinical research
is needed to document the potential add on benefit of more
advanced biomarkers like CysC in neonatal medicine.
Different authors described a progressive physiological
decrease in CysC values throughout infancy, with subsequent
stabilization to age-independent reference values after the
first year of life (0.57–1.12 mg/l) [1,9,13,20,21,31]. This
means that – similar to creatinine – age-specific reference
values in early infancy are needed before we can consider to
integrate this biomarker into neonatal practice as a sensitive
and specific marker to discriminate between physiology and
pathophysiology (i.c. renal dysfunction) [7,40,41]. Moreover,
CysC values should be compared to golden standard clear-
ance assessment tools [e.g. inulin clearance, 51Chrome
ethylene diamine tetra acetic acid (EDTA), 99mTechnecium
diethylene triamine penta acetic acid (DTPA)] to confirm that
CysC values can be converted to GFR estimates. At present,
we are only aware of one study in 20 preterm infants that
linked CysC values to inuline clearance (correlation¼ 0.766)
(Table 3) [33].
Based on the currently retrieved information, an extensive
range (5-fold) in serum CysC observations in early infancy
has been documented, only in part explained by renal
(patho)physiology. This can be further improved by the use
of assay specific reference values. Such reference values
should be adapted to the clinical characteristics (e.g. weight,
gestational or postnatal age) and compared to inulin clearance
or similar as golden standard for GFR estimation. Besides the
search for new biomarkers, we feel strongly that the efforts
made to standardize creatinine assays toward IDMS also hold
an unique opportunity to develop serum creatinine reference
values and centiles for creatinine in (pre)term neonates
[6,7,40,41]. A research effort similar to the CALIPER
(Canadian Laboratory Initiative on Pediatric Reference inter-
vals) initiative, but focussed on early infancy reference values
is mandatory [7,15,40,41] to really disentangle the signal
from the noise.
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